Article Text

Download PDFPDF

Cytomegalovirus containing TRP2 antigen provides protective immunity against the poorly immunogenic B16BL6-D5 melanoma
  1. Michael Neuberger1,
  2. Shawn M Jensen1,
  3. Guangwu Xu4,
  4. Tameka Smith4,
  5. Hong-Ming Hu2,
  6. Ann B Hill4,
  7. Carlo B Bifulco3 and
  8. Bernard A Fox1,4
  1. Aff1 grid.415337.7Laboratory of Molecular and Tumor Immunology, Robert W Franz Cancer Research Center, Earle A Chiles Research InstituteProvidence Cancer Center Portland OR USA
  2. Aff2 grid.415337.7Laboratory of Cancer Immunobiology, Robert W Franz Cancer Research Center, Earle A Chiles Research InstituteProvidence Cancer Center Portland OR USA
  3. Aff3 grid.415337.7Department of PathologyProvidence Cancer Center Portland OR USA
  4. Aff4 grid.5288.70000000097585690Molecular Microbiology and ImmunologyOregon Health & Science University Portland OR USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Cytomegalovirus is known to induce long-lived humoral and cellular immune responses that persist and increase over time. In humans on average more than 5% of T cells are CMV-reactive. We have previously reported that mouse cytomegalovirus (MCMV) encoding the unmodified TRP2 protein can induce immunity that protects mice from challenge with the weakly immunogenic B16-F10 melanoma [Xu 2013]. This protective immunity could be induced in mice with pre-existing immunity to MCMV, overcoming a critical hurdle to the clinical application of this strategy. Surprisingly, this immunity to TRP2 was mediated by antibody. We have extended these observations to the poorly immunogenic B16BL6-D5 (D5) melanoma model, where we now report that vaccination also provides protective immunity. While anti-TRP2 immunity induced by MCMV is humoral, it is as effective as vaccination with a GM-CSF-secreting (GVAX) vaccine (D5-G6) that induces tumor-specific T cell immunity. When we evaluated MCMV-TRP2 in a therapeutic model, the vaccine was ineffective as a single agent. We went on to investigate whether the "inflating" immunity that MCMV is well known for would lead to the co-development of a T cell response long-term. Mice were vaccinated with MCMV-TRP2 and followed long-term. Half of these mice were challenged with viable D5 on day 14. Controls included mice that were vaccinated with D5-G6 and followed long-term. After more than 190 days from the initial vaccination, mice were sacrificed and spleen and lymph node cells were interrogated for an IFN-γ response following stimulation with D5, murine sarcoma cells, or a peptide specific for MCMV. As expected, a large IFN-γ response was elicited by the MCMV peptide in MCMV-vector immunized mice. In addition all vaccinated animals developed a detectable IFN-γ response to the D5 melanoma. The intensity of the T cell response was similar in mice receiving MCMV-TRP2 and D5-G6. Studies are ongoing to characterize the targets of this T cell response and evaluate the mechanism(s) of MCMV-TRP2-induced tumor elimination. While preliminary, the well-established ability of CMV to induce and maintain high-frequency antigen-specific responses, combined with our results, suggest that this strategy may provide an opportunity to augment the anti-cancer immune responses.